Management of difficult multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Update 2012

Respirology

Volumn 18, Issue 1, 2013, Pages 8-21

  Chang, Kwok Chiu ^a   Yew, Wing Wai ^b  

^a DEPARTMENT OF HEALTH   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

human immunodeficiency virus; multidrug resistant; prevention; treatment; tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; THIOAMIDE; THIORIDAZINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

AIRBORNE INFECTION; ARTICLE; DIRECTLY OBSERVED THERAPY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LIVER TOXICITY; LUNG RESECTION; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENT CARE; PALLIATIVE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT COURSE THERAPY; SPUTUM CULTURE; TREATMENT DURATION; TUBERCULOSIS CONTROL;

EID: 84871847805     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02257.x     Document Type: Article

References (228)

1. Yew WW, Chan CK, Chau CH, et al,. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-51.
2. Leimane V, Riekstina V, Holtz TH, et al,. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-26.
3. Chan ED, Laurel V, Strand MJ, et al,. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2004; 169: 1103-9.
4. Migliori GB, Lange C, Girardi E, et al,. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur. Respir. J. 2008; 31: 904-5.
5. Kim DH, Kim HJ, Park S-K, et al,. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2010; 182: 113-9.
6. Chan ED, Strand MJ, Iseman MD,. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB. Clin. Infect. Dis. 2009; 48: e50-52.
7. Migliori GB, Lange C, Centis R, et al,. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur. Respir. J. 2008; 31: 1155-9.
8. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 1948; 2: 769-82.
9. Zhang Y, Yew WW,. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2009; 13: 1320-30.
10. Orenstein EW, Basu S, Shah NS, et al,. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis. 2009; 9: 153-61.
11. Migliori GB, Besozzi G, Girardi E, et al,. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur. Respir. J. 2007; 30: 623-6.
12. Shah NS, Pratt R, Armstrong L, et al,. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008; 300: 2153-60.
13. Mitnick CD, Shin SS, Seung KJ, et al,. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 2008; 359: 563-74.
14. Kim H-R, Hwang SS, Kim HJ, et al,. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin. Infect. Dis. 2007; 45: 1290-5.
15. Eker B, Ortmann J, Migliori GB, et al,. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerging Infect. Dis. 2008; 14: 1700-6.
16. Keshavjee S, Gelmanova IY, Farmer PE, et al,. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403-9.
17. Gandhi NR, Shah NS, Andrews JR, et al,. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am. J. Respir. Crit. Care Med. 2010; 181: 80-6.
18. World Health Organization. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2011.16. World Health Organization, Geneva, 2011.
19. Zhao Y, Xu S, Wang L, et al,. National survey of drug-resistant tuberculosis in China. N. Engl. J. Med. 2012; 366: 2161-70.
20. Gler MT, Macalintal LE, Raymond L, et al,. Multidrug-resistant tuberculosis among previously treated patients in the Philippines. Int. J. Tuberc. Lung Dis. 2011; 15: 652-6.
21. Matthys F, Rigouts L, Sizaire V, et al,. Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. Plos ONE 2009; 4: e7954.
22. Malla P, Kanitz EE, Akhtar M, et al,. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. Plos ONE 2009; 4: e8313.
23. van Halsema CL, Fielding KL, Chihota VN, et al,. Trends in drug-resistant tuberculosis in a gold-mining workforce in South Africa, 2002-2008. Int. J. Tuberc. Lung Dis. 2012; 16: 967-73.
24. Blöndal K, Viiklepp P, Guðmundsson LJ, et al,. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2012; 16: 1228-33.
25. Liang L, Wu Q, Gao L, et al,. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax 2012; 67: 632-8.
26. Banu S, Mahmud AM, Rahman MT, et al,. Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh. Plos ONE 2012; 7: e40545.
27. Andrews JR, Shah NS, Weissman D, et al,. Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community. Plos ONE 2010; 5: e15735.
28. Lomtadze N, Aspindzelashvili R, Janjgava M, et al,. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int. J. Tuberc. Lung Dis. 2009; 13: 68-73.
29. Chaisson RE, Martinson NA,. Tuberculosis in Africa-combating an HIV-driven crisis. N. Engl. J. Med. 2008; 358: 1089-92.
30. Suchindran S, Brouwer ES, Van Rie A,. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. Plos ONE 2009; 4: e5561.
31. Chaisson RE, Nuermberger EL,. Confronting multidrug-resistant tuberculosis. N. Engl. J. Med. 2012; 366: 2223-4.
32. Medical Research Council. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull. World Health Organ. 1959; 21: 51-144.
33. Fox W,. Ambulatory chemotherapy in a developing country: clinical and epidemiological studies. Bibl. Tuberc. 1963; 17: 28-149.
34. Espinal MA, Dye C,. Can DOTS control multidrug-resistant tuberculosis? Lancet 2005; 365: 1206-9.
35. DeRiemer K, García-García L, Bobadilla-del-Valle M, et al,. Does DOTS work in populations with drug-resistant tuberculosis? Lancet 2005; 365: 1239-45.
36. Chiang C-Y, Schaaf HS,. Management of drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2010; 14: 672-82.
37. World Health Organization. Treatment of tuberculosis: guidelines for national programmes, 3rd edn. WHO/CDS/TB/2003.313. World Health Organization, Geneva, 2003.
38. Caminero JA,. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int. J. Tuberc. Lung Dis. 2008; 12: 869-77.
39. Iseman MD,. MDR-TB and the developing world-a problem no longer to be ignored: the WHO announces 'DOTS Plus' strategy. Int. J. Tuberc. Lung Dis. 1998; 2: 867.
40. Suárez PG, Floyd K, Portocarrero J, et al,. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 2002; 359: 1980-9.
41. Van Deun A, Salim MAH, Das APK, et al,. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int. J. Tuberc. Lung Dis. 2004; 8: 560-7.
42. Fox W, Ellard GA, Mitchison DA,. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 1999; 3: S231-279.
43. Chang KC, Leung CC, Grosset J, et al,. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011; 66: 997-1007.
44. Blomberg B, Spinaci S, Fourie B, et al,. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull. World Health Organ. 2001; 79: 61-8.
45. Bartacek A, Schütt D, Panosch B, et al,. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 2009; 13: 760-6.
46. Lienhardt C, Cook SV, Burgos M, et al,. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 2011; 305: 1415-23.
47. Moulding TS, Le HQ, Rikleen D, et al,. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin. Int. J. Tuberc. Lung Dis. 2004; 8: 743-8.
48. Mitchison DA,. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int. J. Tuberc. Lung Dis. 1998; 2: 10-5.
49. Davidson H, Schluger NW, Feldman PH, et al,. The effects of increasing incentives on adherence to tuberculosis directly observed therapy. Int. J. Tuberc. Lung Dis. 2000; 4: 860-5.
50. Gärden B, Samarina A, Stavchanskaya I, et al,. Food incentives improve adherence to tuberculosis drug treatment among homeless patients in Russia. Scand. J. Caring Sci. 2012; doi: 10.1111/j.1471-6712.2012.01009.x [Epub ahead of print].
51. Martins N, Morris P, Kelly PM,. Food incentives to improve completion of tuberculosis treatment: randomised controlled trial in Dili, Timor-Leste. BMJ 2009; 339: b4248.
52. Gelmanova IY, Taran DV, Mishustin SP, et al,. 'Sputnik': a programmatic approach to improve tuberculosis treatment adherence and outcome among defaulters. Int. J. Tuberc. Lung Dis. 2011; 15: 1373-9.
53. Khan MS, Suwannapong N, Howteerakul N, et al,. Improvement of district hospital service system to increase treatment adherence among tuberculosis patients in Pakistan. Southeast Asian J. Trop. Med. Public Health 2011; 42: 664-73.
54. Chimbanrai B, Fungladda W, Kaewkungwal J, et al,. Treatment-seeking behaviors and improvement in adherence to treatment regimen of tuberculosis patients using intensive triad-model program, Thailand. Southeast Asian J. Trop. Med. Public Health 2008; 39: 526-41.
55. Thiam S, LeFevre AM, Hane F, et al,. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA 2007; 297: 380-6.
56. Uplekar M, Pathania V, Raviglione M,. Private practitioners and public health: weak links in tuberculosis control. Lancet 2001; 358: 912-6.
57. Murthy KJ, Frieden TR, Yazdani A, et al,. Public-private partnership in tuberculosis control: experience in Hyderabad, India. Int. J. Tuberc. Lung Dis. 2001; 5: 354-9.
58. Uplekar M,. Involving private health care providers in delivery of TB care: global strategy. Tuberculosis (Edinb.) 2003; 83: 156-64.
59. Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC). Tuberculosis Coalition for Technical Assistance, The Hague, 2006.
60. Lal SS, Uplekar M, Katz I, et al,. Global Fund financing of public-private mix approaches for delivery of tuberculosis care. Trop. Med. Int. Health 2011; 16: 685-92.
61. Malmborg R, Mann G, Squire SB,. A systematic assessment of the concept and practice of public-private mix for tuberculosis care and control. Int. J. Equity Health 2011; 10: 49.
62. Munsiff SS, Ahuja SD, Li J, et al,. Public-private collaboration for multidrug-resistant tuberculosis control in New York City. Int. J. Tuberc. Lung Dis. 2006; 10: 639-48.
63. Quelapio MID, Mira NRC, Orillaza-Chi RB, et al,. Responding to the multidrug-resistant tuberculosis crisis: mainstreaming programmatic management to the Philippine National Tuberculosis Programme. Int. J. Tuberc. Lung Dis. 2010; 14: 751-7.
64. Quy HT, Lönnroth K, Lan NTN, et al,. Treatment results among tuberculosis patients treated by private lung specialists involved in a public-private mix project in Vietnam. Int. J. Tuberc. Lung Dis. 2003; 7: 1139-46.
65. Probandari A, Lindholm L, Stenlund H, et al,. Missed opportunity for standardized diagnosis and treatment among adult tuberculosis patients in hospitals involved in public-private mix for directly observed treatment short-course strategy in Indonesia: a cross-sectional study. BMC Health Serv. Res. 2010; 10: 113.
66. Sinanovic E, Kumaranayake L,. Quality of tuberculosis care provided in different models of public-private partnerships in South Africa. Int. J. Tuberc. Lung Dis. 2006; 10: 795-801.
67. Sinanovic E, Kumaranayake L,. The motivations for participation in public-private partnerships for the provision of tuberculosis treatment in South Africa. Glob. Public Health 2010; 5: 479-92.
68. World Health Organization. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis: policy statement. WHO/HTM/TB/2011.8. World Health Organization, Geneva, 2011.
69. World Health Organization. Framework for implementing new tuberculosis diagnostics. 2010. [Accessed 12 Aug 2012.] Available from URL: http://www.who.int/tb/laboratory/whopolicyframework-july10-revnov10.pdf
70. Oxlade O, Falzon D, Menzies D,. The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis. Eur. Respir. J. 2012; 39: 626-34.
71. Dowdy DW, Chaisson RE, Moulton LH, et al,. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS 2006; 20: 751-62.
72. World Health Organization. Policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). 2008. [Accessed 12 Aug 2012.] Available from URL: http://www.who.int/ tb/features-archive/policy-statement.pdf
73. World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. WHO/HTM/TB/2011.4. World Health Organization, Geneva, 2011.
74. World Health Organization. Tuberculosis diagnostics: Xpert MTB/RIF test. 2012. [Accessed 12 Aug 2012.] Available from URL: http://www.who.int/entity/tb/ features-archive/factsheet-xpert-may2011update.pdf
75. World Health Organization. Policy statement: noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrug-resistant tuberculosis. WHO/HTM/TB/2011.9. World Health Organization, Geneva, 2011.
76. Kiet VS, Lan NTN, An DD, et al,. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 2010; 48: 2934-9.
77. Huang W-L, Chi T-L, Wu M-H, et al,. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 2011; 49: 2502-8.
78. Chang KC, Yew WW, Chan RCY,. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 2010; 65: 1551-61.
79. Van Deun A, Martin A, Palomino JC,. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int. J. Tuberc. Lung Dis. 2010; 14: 131-40.
80. Riley RL, Mills CC, Nyka W, et al,. Aerial dissemination of pulmonary tuberculosis. A two-year study of contagion in a tuberculosis ward. 1959. Am. J. Epidemiol. 1995; 142: 3-14.
81. Borrell S, Gagneux S,. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2009; 13: 1456-66.
82. Nodieva A, Jansone I, Broka L, et al,. Recent nosocomial transmission and genotypes of multidrug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2010; 14: 427-33.
83. Leung ECC, Leung CC, Kam KM, et al,. Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city. Eur. Respir. J. 2012; doi: 10.1183/09031936.00071212 [Epub ahead of print].
84. O'Donnell MR, Jarand J, Loveday M, et al,. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann. Intern. Med. 2010; 153: 516-22.
85. Moodley P, Shah NS, Tayob N, et al,. Spread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa. Plos ONE 2011; 6: e17513.
86. Basu S, Andrews JR, Poolman EM, et al,. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007; 370: 1500-7.
87. Dharmadhikari AS, Mphahlele M, Stoltz A, et al,. Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. Am. J. Respir. Crit. Care Med. 2012; 185: 1104-9.
88. Shenoi SV, Escombe AR, Friedland G,. Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts. Clin. Infect. Dis. 2010; 50 (Suppl. 3): S231-237.
89. London L,. Confinement for extensively drug-resistant tuberculosis: balancing protection of health systems, individual rights and the public's health. Int. J. Tuberc. Lung Dis. 2009; 13: 1200-9.
90. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. WHO/HTM/TB/2009.419. World Health Organization, Geneva, 2009.
91. Golub JE, Saraceni V, Cavalcante SC, et al,. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-8.
92. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. World Health Organization, Geneva, 2011.
93. Martinson NA, Barnes GL, Moulton LH, et al,. New regimens to prevent tuberculosis in adults with HIV infection. N. Engl. J. Med. 2011; 365: 11-20.
94. Singla N, Singla R, Jain G, et al,. Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India. Int. J. Tuberc. Lung Dis. 2011; 15: 1326-30.
95. van der Werf MJ, Langendam MW, Sandgren A, et al,. Lack of evidence to support policy development for management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int. J. Tuberc. Lung Dis. 2012; 16: 288-96.
96. Schaaf HS, Marais BJ,. Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. Paediatr. Respir. Rev. 2011; 12: 31-8.
97. Holland DP, Sanders GD, Hamilton CD, et al,. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. Plos ONE 2012; 7: e30194.
98. World Health Organization. Antiretroviral treatment as prevention (TasP) of HIV and TB: 2012 update. WHO/HIV/2012.12. World Health Organization, Geneva, 2012.
99. Suthar AB, Lawn SD, del Amo J, et al,. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. Plos Med. 2012; 9: e1001270.
100. World Health Organization. Treatment of tuberculosis: guidelines-4th ed. WHO/HTM/TB/2009.420. World Health Organization, Geneva, 2010.
101. Blumberg HM, Burman WJ, Chaisson RE, et al,. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 2003; 167: 603-62.
102. ISRCTN Register. [Accessed 12 Aug 2012.] Available from URL: http://www.controlled-trials.com/ISRCTN78372190/78372190
103. Van Deun A, Maug AKJ, Salim MAH, et al,. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2010; 182: 684-92.
104. Payen MC, De Wit S, Martin C, et al,. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis [Case study]. Int. J. Tuberc. Lung Dis. 2012; 16: 558-60.
105. Abbate E, Vescovo M, Natiello M, et al,. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J. Antimicrob. Chemother. 2012; 67: 473-7.
106. Caminero JA, Sotgiu G, Zumla A, et al,. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 2010; 10: 621-9.
107. Yew WW, Lange C, Leung CC,. Treatment of tuberculosis: update 2010. Eur. Respir. J. 2011; 37: 441-62.
108. Geiseler PJ, Manis RD Jr, Maddux MS,. Dosage of antituberculous drugs in obese patients. Am. Rev. Respir. Dis. 1985; 131: 944-6.
109. Hasenbosch RE, Alffenaar JWC, Koopmans SA, et al,. Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. Int. J. Tuberc. Lung Dis. 2008; 12: 967-71.
110. Fish DN, Chow AT,. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 1997; 32: 101-19.
111. Espinal MA, Kim SJ, Suarez PG, et al,. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-45.
112. Aziz MA, Wright A, Laszlo A, et al,. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368: 2142-54.
113. Katiyar SK, Bihari S, Prakash S, et al,. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2008; 12: 139-45.
114. Peloquin CA,. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62: 2169-83.
115. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402. World Health Organization, Geneva, 2008.
116. Zhang Y, Chang KC, Leung C-C, et al,. 'ZS-MDR-TB' versus 'ZR-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerg. Microbes Infect. 2012; 1: e5.
117. Tousek J, Jancik E, Zelenka M, et al,. The results of treatment in patients with cultures resistant to streptomycin, isoniazid and PAS: a five-year follow-up. Tubercle 1967; 48: 27-31.
118. Zierski M, Zachara A,. Late results in re-treatment of patients with pulmonary tuberculosis. Tubercle 1970; 51: 172-7.
119. Somner AR, Brace AA,. Late results of treatment of chronic drug-resistant pulmonary tuberculosis. Br. Med. J. 1966; 1: 775-8.
120. Mitnick C, Bayona J, Palacios E, et al,. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N. Engl. J. Med. 2003; 348: 119-28.
121. Falzon D, Jaramillo E, Schünemann HJ, et al,. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur. Respir. J. 2011; 38: 516-28.
122. Chang K-C, Leung C-C, Yew W-W, et al,. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob. Agents Chemother. 2012; doi: 10.1128/AAC.01300-12 [Epub ahead of print].
123. Chang KC, Yew WW, Zhang Y,. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob. Agents Chemother. 2011; 55: 4499-505.
124. Jacobson KR, Tierney DB, Jeon CY, et al,. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis. 2010; 51: 6-14.
125. Zvonar R,. Gatifloxacin-induced dysglycemia. Am. J. Health Syst. Pharm. 2006; 63: 2087-92.
126. Poissy J, Aubry A, Fernandez C, et al,. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob. Agents Chemother. 2010; 54: 4765-71.
127. Gumbo T, Louie A, Deziel MR, et al,. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect. Dis. 2004; 190: 1642-51.
128. Johnson JL, Hadad DJ, Boom WH, et al,. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 2006; 10: 605-12.
129. Maus CE, Plikaytis BB, Shinnick TM,. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2005; 49: 3192-7.
130. Satti H, Mafukidze A, Jooste PL, et al,. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. Int. J. Tuberc. Lung Dis. 2012; 16: 468-72.
131. Thee S, Zöllner EW, Willemse M, et al,. Abnormal thyroid function tests in children on ethionamide treatment. Int. J. Tuberc. Lung Dis. 2011; 15: 1191-3. i.
132. Mizutani H, Horiba M, Shindoh J, et al,. Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism. Kekkaku 2001; 76: 667-72.
133. Keshavjee S, Gelmanova IY, Shin SS, et al,. Hepatotoxicity during treatment for multidrug-resistant tuberculosis: occurrence, management and outcome. Int. J. Tuberc. Lung Dis. 2012; 16: 596-603.
134. Loddenkemper R, Schaberg T,. Treatment of MDR-TB: is hepatotoxicity a problem? Int. J. Tuberc. Lung Dis. 2012; 16: 571.
135. Alcalá L, Ruiz-Serrano MJ, Pérez-Fernández Turégano C, et al,. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob. Agents Chemother. 2003; 47: 416-7.
136. Dietze R, Hadad DJ, McGee B, et al,. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 2008; 178: 1180-5.
137. Erturan Z, Uzun M,. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int. J. Antimicrob. Agents 2005; 26: 78-80.
138. Tato M, de la Pedrosa EG-G, Cantõn R, et al,. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int. J. Antimicrob. Agents 2006; 28: 75-8.
139. Sotgiu G, Centis R, D'Ambrosio L, et al,. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 2012; doi: 10.1183/09031936.00022912 [Epub ahead of print].
140. Cox H, Ford N,. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]. Int. J. Tuberc. Lung Dis. 2012; 16: 447-54.
141. Koh W-J, Shim TS,. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis-authors' response. J. Antimicrob. Chemother. 2009; 64: 1119-20.
142. Koh W-J, Kang YR, Jeon K, et al,. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J. Antimicrob. Chemother. 2012; 67: 1503-7.
143. Yew WW, Chang KC, Chau CH,. Comment on: daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J. Antimicrob. Chemother. 2009; 64: 1119; author reply 1119-20.
144. Hugonnet J-E, Tremblay LW, Boshoff HI, et al,. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009; 323: 1215-8.
145. Martins M, Viveiros M, Couto I, et al,. Targeting human macrophages for enhanced killing of intracellular XDR-TB and MDR-TB. Int. J. Tuberc. Lung Dis. 2009; 13: 569-73.
146. Amaral L, Viveiros M,. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. Int. J. Antimicrob. Agents 2012; 39: 376-80.
147. Dauby N, Muylle I, Mouchet F, et al,. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr. Infect. Dis. J. 2011; 30: 812-3.
148. Xu H-B, Jiang R-H, Tang S-J, et al,. Role of clofazimine in the treatment of multidrug-resistant tuberculosis: a retrospective observational cohort assessment. J. Antimicrob. Chemother. 2012; doi: 10.1093/jac/dks077 [Epub ahead of print].
149. Nadler JP, Berger J, Nord JA, et al,. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991; 99: 1025-6.
150. Chambers HF, Kocagöz T, Sipit T, et al,. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 1998; 26: 874-7.
151. Bergmann JS, Woods GL,. In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 1998; 2: 621-6.
152. Iwanaga T, Yokota K, Kishikawa R, et al,. The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis. Kekkaku 1997; 72: 9-13.
153. Cynamon MH, Palmer GS,. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1983; 24: 429-31.
154. Donald PR, Sirgel FA, Venter A, et al,. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand. J. Infect. Dis. 2001; 33: 466-9.
155. Varshochi M, Rastgar MH, Raffi A, et al,. In-vitro susceptibility of Mycobacterium tuberculosis to amoxicillin-clavulanate. Iran. J. Clin. Infect. Dis. 2006; 1: 121-5.
156. Grosset JH, Singer TG, Bishai WR,. New drugs for the treatment of tuberculosis: hope and reality. Int. J. Tuberc. Lung Dis. 2012; 16: 1005-14.
157. Andries K, Verhasselt P, Guillemont J, et al,. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
158. Ibrahim M, Andries K, Lounis N, et al,. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother. 2007; 51: 1011-5.
159. Veziris N, Ibrahim M, Lounis N, et al,. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med. 2009; 179: 75-9.
160. Diacon AH, Pym A, Grobusch M, et al,. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 2009; 360: 2397-405.
161. Diacon AH, Donald PR, Pym A, et al,. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 2012; 56: 3271-6.
162. Matsumoto M, Hashizume H, Tomishige T, et al,. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. Plos Med. 2006; 3: e466.
163. Hu Y, Coates ARM, Mitchison DA,. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2008; 12: 69-73.
164. Nuermberger E, Tyagi S, Tasneen R, et al,. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2008; 52: 1522-4.
165. Tasneen R, Tyagi S, Williams K, et al,. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2008; 52: 3664-8.
166. Gler MT, Skripconoka V, Sanchez-Garavito E, et al,. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 2012; 366: 2151-60.
167. Pierre-Audigier C, Surcouf C, Cadet-Daniel V, et al,. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2012; 16: 221-3. i-ii.
168. Kim HJ, Kwak HK, Lee J, et al,. Patterns of pncA mutations in drug-resistant Mycobacterium tuberculosis isolated from patients in South Korea. Int. J. Tuberc. Lung Dis. 2012; 16: 98-103.
169. Milburn H, Ashman N, Davies P, et al,. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010; 65: 557-70.
170. Chang KC, Yew WW, Cheung SW, et al,. Extensively drug-resistant tuberculosis (XDR-TB) treated with daily/intermittent linezolid. Abstract number: L1-1488. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept 17-20, 2011. Chicago, IL, USA.
171. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. World Health Organization, Geneva, 2009.
172. Department of Health and Human Services. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012. [Accessed 12 Aug 2012.] Available from URL: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
173. Abdool Karim SS, Naidoo K, Grobler A, et al,. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 2010; 362: 697-706.
174. Abdool Karim SS, Naidoo K, Grobler A, et al,. Integration of antiretroviral therapy with tuberculosis treatment. N. Engl. J. Med. 2011; 365: 1492-501.
175. Havlir DV, Kendall MA, Ive P, et al,. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 2011; 365: 1482-91.
176. Blanc F-X, Sok T, Laureillard D, et al,. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N. Engl. J. Med. 2011; 365: 1471-81.
177. Shin S, Furin J, Bayona J, et al,. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc. Sci. Med. 2004; 59: 1529-39.
178. Seung KJ, Omatayo DB, Keshavjee S, et al,. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. Plos ONE 2009; 4: e7186.
179. Heller T, Lessells RJ, Wallrauch CG, et al,. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int. J. Tuberc. Lung Dis. 2010; 14: 420-6.
180. Brust JCM, Shah NS, Scott M, et al,. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int. J. Tuberc. Lung Dis. 2012; 16: 998-1004.
181. Iseman MD, Madsen L, Goble M, et al,. Surgical intervention in the treatment of pulmonary disease caused by drug-resistant Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 1990; 141: 623-5.
182. Kim HJ, Kang CH, Kim YT, et al,. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur. Respir. J. 2006; 28: 576-80.
183. Törün T, TahaoÄlu K, Ozmen I, et al,. The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2007; 11: 979-85.
184. Shiraishi Y, Katsuragi N, Kita H, et al,. Experience with pulmonary resection for extensively drug-resistant tuberculosis. Interact. Cardiovasc. Thorac. Surg. 2008; 7: 1075-8.
185. Kim DH, Kim HJ, Park S-K, et al,. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2008; 178: 1075-82.
186. Jeon DS, Kim DH, Kang HS, et al,. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2009; 13: 594-600.
187. Kwon YS, Kim YH, Suh GY, et al,. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin. Infect. Dis. 2008; 47: 496-502.
188. Treasure RL, Seaworth BJ,. Current role of surgery in Mycobacterium tuberculosis. Ann. Thorac. Surg. 1995; 59: 1405-7. Discussion 1408-9.
189. van Leuven M, De Groot M, Shean KP, et al,. Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis. Ann. Thorac. Surg. 1997; 63: 1368-72. Discussion 1372-3.
190. Sung SW, Kang CH, Kim YT, et al,. Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis. Eur. J. Cardiothorac Surg. 1999; 16: 187-93.
191. Pomerantz BJ, Cleveland JC Jr, Olson HK, et al,. Pulmonary resection for multi-drug resistant tuberculosis. J. Thorac. Cardiovasc. Surg. 2001; 121: 448-53.
192. Chiang CY, Yu MC, Bai KJ, et al,. Pulmonary resection in the treatment of patients with pulmonary multidrug-resistant tuberculosis in Taiwan. Int. J. Tuberc. Lung Dis. 2001; 5: 272-7.
193. Park SK, Lee CM, Heu JP, et al,. A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2002; 6: 143-9.
194. Naidoo R, Reddi A,. Lung resection for multidrug-resistant tuberculosis. Asian Cardiovasc. Thorac. Ann. 2005; 13: 172-4.
195. Takeda S, Maeda H, Hayakawa M, et al,. Current surgical intervention for pulmonary tuberculosis. Ann. Thorac. Surg. 2005; 79: 959-63.
196. Kir A, Inci I, Torun T, et al,. Adjuvant resectional surgery improves cure rates in multidrug-resistant tuberculosis. J. Thorac. Cardiovasc. Surg. 2006; 131: 693-6.
197. Somocurcio JG, Sotomayor A, Shin S, et al,. Surgery for patients with drug-resistant tuberculosis: report of 121 cases receiving community-based treatment in Lima, Peru. Thorax 2007; 62: 416-21.
198. Mohsen T, Zeid AA, Haj-Yahia S,. Lobectomy or pneumonectomy for multidrug-resistant pulmonary tuberculosis can be performed with acceptable morbidity and mortality: a seven-year review of a single institution's experience. J. Thorac. Cardiovasc. Surg. 2007; 134: 194-8.
199. Wang H, Lin H, Jiang G,. Pulmonary resection in the treatment of multidrug-resistant tuberculosis: a retrospective study of 56 cases. Ann. Thorac. Surg. 2008; 86: 1640-5.
200. Shiraishi Y, Katsuragi N, Kita H, et al,. Aggressive surgical treatment of multidrug-resistant tuberculosis. J. Thorac. Cardiovasc. Surg. 2009; 138: 1180-4.
201. Dravniece G, Cain KP, Holtz TH, et al,. Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. Eur. Respir. J. 2009; 34: 180-3.
202. Park S-K, Kim J-H, Kang H, et al,. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int. J. Infect. Dis. 2009; 13: 170-5.
203. Kang M-W, Kim HK, Choi YS, et al,. Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis. Ann. Thorac. Surg. 2010; 89: 1597-602.
204. Man MA, Nicolau D,. Surgical treatment to increase the success rate of multidrug-resistant tuberculosis. Eur. J. Cardiothorac Surg. 2012; 42: e9-12.
205. Gegia M, Kalandadze I, Kempker RR, et al,. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int. J. Infect. Dis. 2012; 16: e391-6.
206. Dewan RK, Singh S, Kumar A, et al,. Thoracoplasty: an obsolete procedure? Indian J. Chest Dis. Allied Sci. 1999; 41: 83-8.
207. Jouveshomme S, Dautzenberg B, Bakdach H, et al,. Preliminary results of collapse therapy with plombage for pulmonary disease caused by multidrug-resistant mycobacteria. Am. J. Respir. Crit. Care Med. 1998; 157: 1609-15.
208. Motus IY, Skorniakov SN, Sokolov VA, et al,. Reviving an old idea: can artificial pneumothorax play a role in the modern management of tuberculosis? Int. J. Tuberc. Lung Dis. 2006; 10: 571-7.
209. Condos R, Schluger NW,. Cytokine-based approaches to the treatment of multidrug-resistant tuberculosis. BioDrugs 1999; 11: 165-73.
210. Johnson BJ, Bekker LG, Rickman R, et al,. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber. Lung Dis. 1997; 78: 195-203.
211. Palmero D, Eiguchi K, Rendo P, et al,. Phase II trial of recombinant interferon-alpha2b in patients with advanced intractable multidrug-resistant pulmonary tuberculosis: long-term follow-up. Int. J. Tuberc. Lung Dis. 1999; 3: 214-8.
212. Giosuè S, Casarini M, Ameglio F, et al,. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. Eur. Cytokine Netw. 2000; 11: 99-104.
213. Grahmann PR, Braun RK,. A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. Int. J. Tuberc. Lung Dis. 2008; 12: 636-44.
214. Stanford JL, Stanford CA, Grange JM, et al,. Does immunotherapy with heat-killed Mycobacterium vaccae offer hope for the treatment of multi-drug-resistant pulmonary tuberculosis? Respir. Med. 2001; 95: 444-7.
215. Churchyard GJ, Kaplan G, Fallows D, et al,. Advances in immunotherapy for tuberculosis treatment. Clin. Chest Med. 2009; 30: 769-82. ix.
216. Uhlin M, Andersson J, Zumla A, et al,. Adjunct immunotherapies for tuberculosis. J. Infect. Dis. 2012; 205 (Suppl. 2): S325-34.
217. Ralph AP, Kelly PM, Anstey NM,. L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis. Trends Microbiol. 2008; 16: 336-44.
218. Wejse C, Gomes VF, Rabna P, et al,. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2009; 179: 843-50.
219. World Health Organization. Management of MDR-TB: a field guide. A companion document to guidelines for programmatic management of drug-resistant tuberculosis: integrated management of adolescent and adult illness (IMAI). WHO/HTM/TB/2008.402a. World Health Organization, Geneva, 2009.
220. World Health Organization. Palliative care: symptom management and end-of-life care. Integrated management of adolescent and adult illness. Interim guidelines for first-level facility health workers. WHO/CDS/IMAI/2004.4 Rev. 1. World Health Organization, Geneva, 2004.
221. Yew WW, Leung CC,. Management of multidrug-resistant tuberculosis: update 2007. Respirology 2008; 13: 21-46.
222. World Health Organization. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. WHO/HTM/STB/2010.2. World Health Organization, Geneva, 2011.
223. Migliori GB, Loddenkemper R, Blasi F, et al,. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is 'science' enough to tackle the epidemic? Eur. Respir. J. 2007; 29: 423-7.
224. Crofton J,. Drug treatment of tuberculosis. II. Treatment of patients with tubercle bacilli resistant to standard chemotherapy. Br. Med. J. 1960; 2: 449-51.
225. Jackson S, Sleigh AC, Wang GJ, et al,. Poverty and the economic effects of TB in rural China. Int. J. Tuberc. Lung Dis. 2006; 10: 1104-10.
226. Keshavjee S, Gelmanova IY, Pasechnikov AD, et al,. Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Ann. N. Y. Acad. Sci. 2008; 1136: 1-11.
227. World Health Organization. Short-term priorities for antiretroviral drug optimization: meeting report. World Health Organization, Geneva, 2011.
228. World Health Organization. The strategic use of antiretrovirals to help end the HIV epidemic. World Health Organization, Geneva, 2012.